PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Abatacept - Rheumatoid arthritis
PAD Profile : Abatacept - Rheumatoid arthritis Important
Keywords :
RA, Biologic, NICE, immunosuppressant, T-cell co-stimulation inhibitor, DMARD, Bdmard, Disease modulating, Rheumatology
Brand Names Include :
Orencia
Important Information :
Severe disease only. NON-FORMULARY for moderate disease
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).
01 September 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Abatacept is NON-FORMULARY for moderate disease.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agrees with the recommendations made in NICE TA715.
Abatacept for moderately active Rheumatoid Arthritis was not recommended by NICE and will be given a NON-FORMULARY traffic light status for this indication. The current treatment pathway is attached below.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs